Sign up to save your podcasts
Or
Share Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME credits: 0.50
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/
This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and adjuvant immunotherapy in locally advanced disease then discuss novel targeted and immunotherapy-based approaches that are showing promise in recurrent/metastatic disease. Safety profiles, patient-reported outcomes, and multidisciplinary considerations are addressed to support thoughtful integration of these therapies into real-world practice. These insights reinforce evolving strategies designed to enhance outcomes for patients across the full HNSCC spectrum.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/
This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and adjuvant immunotherapy in locally advanced disease then discuss novel targeted and immunotherapy-based approaches that are showing promise in recurrent/metastatic disease. Safety profiles, patient-reported outcomes, and multidisciplinary considerations are addressed to support thoughtful integration of these therapies into real-world practice. These insights reinforce evolving strategies designed to enhance outcomes for patients across the full HNSCC spectrum.
=